论文标题
COVID早期肺炎早期的大量病毒复制和细胞病变作用
Massive viral replication and cytopathic effects in early COVID-19 pneumonia
论文作者
论文摘要
SARS-COV-2是Covid-19急性呼吸道疾病的原因，与其前身，MERS和SARS一样，可能是严重的，致命的1-4。到2020年4月，Covid-19的感染已成为全球大流行，感染了近300万，死亡超过200,000人。尚待确定病毒复制和细胞病毒作用或免疫病理宿主对Covid-19肺部感染严重和致命结果的相对贡献。在这里，我们表明SARS-COV-2复制和II型肺泡肺核细胞的细胞病变作用会导致没有肺部症状史的个体局灶性肺损伤。这些发现表明，早期有效抗病毒药物治疗的潜在益处可以防止发生严重和致命的肺炎。
SARS-CoV-2 is the cause of COVID-19 acute respiratory illness that like its predecessors, MERS and SARS, can be severe and fatal 1-4. By April of 2020, COVID-19 infections had become a worldwide pandemic with nearly 3 million infections and over 200,000 deaths. The relative contributions of virus replication and cytopathic effects or immunopathological host responses to the severe and fatal outcomes of COVID-19 lung infections have as yet to be determined. Here we show that SARS-CoV-2 replication and cytopathic effects in type II alveolar pneumocytes causes focal lung injury in an individual with no history of pulmonary symptoms. These findings point to the potential benefit of early effective antiviral treatment to prevent progression to severe and fatal COVID-19 pneumonia.
